Remacemide
Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties. It has been studied for the treatment of acute ischemic stroke,epilepsy,Huntington's disease, and Parkinson's disease.
Because remacemide has only a modest effect on seizure frequency and causes dizziness, it is no longer believed that remacemide will be an effective treatment for epilepsy. Although no such statement has been made about remacemide's potential for treating stroke, Huntington's, or Parkinson's, remacemide is no longer being developed for these conditions.
Remacemide is also known as remacemide hydrochloride, (±)-2-amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, or FPL 12924AA.

This is an excerpt from the article Remacemide from the Wikipedia free encyclopedia. A list of authors is available at Wikipedia.
The article Remacemide at en.wikipedia.org was accessed 807 times in the last 30 days. (as of: 08/16/2014)
Images on Remacemide
Preview image:
Original:
Search results from Google and Bing
1
1
1
Remacemide - Wikipedia, the free encyclopedia
Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties. It has been studied for the treatment of acute ...
en.wikipedia.org/wiki/Remacemide
2
>30
2
Remacemide hydrochloride Supplier | CAS 111686-79-4 | Tocris ...
View and buy high purity Remacemide hydrochloride from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents.
www.tocris.com/dispprod.php?ItemId=56447
3
>30
3
Remacemide « HOPES
Jun 29, 2010 ... Drug Summary: Remacemide (RMC) is a drug that HD researchers hope can alleviate glutamate toxicity in the brains of HD patients.
www.stanford.edu/group/hopes/cgi-bin/wordpress/2010/06/remacemide/
4
>30
4
CARE-HD: Co-enzyme Q10 And Remacemide Evaluation in ...
Page 1 of 3 www.Huntington-Study-Group.org. CARE-HD: Co-enzyme Q10 And Remacemide Evaluation in. Huntington's Disease. No New Treatment, But A ...
www.huntington-study-group.org/Portals/0/ResultsCAREHDTrial.pdf
5
>30
5
A controlled trial of remacemide hydrochloride in Huntington's disease.
Subjects were randomized to receive either placebo or active Remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the ...
www.ncbi.nlm.nih.gov/pubmed/8723144
6
>30
6
Remacemide hydrochloride: a double-blind, placebo-controlled ...
Remacemide hydrochloride has demonstrated neuroprotection in animal models of hypoxia and ischemic stroke. This study assessed the safety, tolerability, and ...
www.ncbi.nlm.nih.gov/pubmed/10471426
7
>30
7
Coenzyme Q10 and remacemide hydrochloride ameliorate motor ...
The CARE-HD study, recently published, evaluated the ability of a combination of coenzyme Q10 (CoQ10) and Remacemide hydrochloride (R) to ameliorate ...
www.ncbi.nlm.nih.gov/pubmed/11716985
8
>30
8
Remacemide hydrochloride | CAS 111686-79-4 | Santa Cruz Biotech
Buy Remacemide hydrochloride (CAS 111686-79-4), an NMDA receptor and sodium channel protein inhibitor, from Santa Cruz. MF: C17H20N2O.HCl, MW: ...
www.scbt.com/datasheet-361307.html
9
>30
9
Remacemide: current status and clinical applications, Expert ...
Remacemide (RMC) is a non-competitive, low-affinity N-methyl-D-aspartate ( NMDA) receptor antagonist that does not cause the behavioural and ...
informahealthcare.com/doi/abs/10.1517/13543784.9.4.871%20
10
>30
10
Therapeutic Effects of Coenzyme Q10 and Remacemide - Journal of ...
Therapeutic Effects of Coenzyme Q10 and Remacemide in. Transgenic Mouse Models of Huntington's Disease. Robert J. Ferrante,1,2 Ole A. Andreassen,3 ...
www.jneurosci.org/content/22/5/1592.full.pdf
Search results for "Remacemide"
Google: approx. 25.700
Remacemide in science
[PDF]Therapeutic Effects of Coenzyme Q10 and Remacemide - Journal of ...
and Neuroscience, Weill Medical College of Cornell University, New York Presbyterian Hospital, ... either coenzyme Q10 or Remacemide significantly extended.
A controlled trial of remacemide hydrochloride in Huntington's disease.
Department of Neurology, University of Rochester Medical Center, New York ... Subjects were randomized to receive either placebo or active Remacemide at ...
Remacemide hydrochloride: a double-blind, placebo-controlled ...
Acute Stroke Unit, University Department of Medicine and Therapeutics, Gardiner ... BACKGROUND AND PURPOSE: Remacemide hydrochloride and its ...
[PDF]CARE-HD: Co-enzyme Q10 And Remacemide Evaluation in ...
The results of the experimental medication Remacemide, under development by. AstraZeneca, and ... University of Rochester Medical Center. But the Huntington ...
Co-enzyme Q10 And Remacemide Evaluation in Huntington ...
CARE-HD is a drug trial for symptomatic individuals done in collaboration with the Huntington Study Group, University of Rochester, New York, USA.
A randomized, controlled trial of remacemide for motor fluctuations ...
Address correspondence and reprint requests to Dr. Steven R. Schwid, University of Rochester Medical Center, Department of Neurology, 601 Elmwood Avenue ...
[PDF]A double-blind, placebo-controlled study of remacemide ...
New York Hospital for Joint Diseases, New York, USA; ‡University of Alabama, ... macokinetics of Remacemide hydrochloride in adult patients (n = 59) with ...
A double-blind, placebo-controlled study of remacemide ...
Aug 1, 2002 ... a New York Hospital for Joint Diseases, New York, USA; b University of Alabama, Birmingham, Alabama, USA; c MINCEP, University of ...
Antiparkinsonian effects of remacemide hydrochloride, a glutamate ...
Oct 8, 2004 ... Antiparkinsonian effects of Remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Brain uptake and biotransformation of remacemide hydrochloride, a ...
Abstract. The brain uptake and biotransformation of Remacemide hydrochloride [( +/-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide monohydrochloride; FPL ...
Books on the term Remacemide
Antiepileptic Drugs
Antiepileptic Drugs
René H. Levy, 2002
binding in the order of 68 |Imol/L and 0.48 [imol/L, respectively (81). In vivo, the difference in potency between Remacemide and its metabolite in inhibiting NMDA - induced seizures and death are less marked than expected from in vitro studies,  ...
Antiepileptic Drugs: Pharmacology and Therapeutics (Handbook of Experimental Pharmacology)
Antiepileptic Drugs: Pharmacology and Therapeutics (Handbook of Experimental Pharmacology)
2011
This volume provides up to date knowledge of the pharmacologies of the various antiepileptic drugs, especially those which have become available since 1984 when the previous edition (Handbook of Experimental Pharmacology, Volume 74: Antiepileptic Drugs, edited by H.-H. Frey and D. Janz) appeared. The data concerning the individual drugs are present...
Pathologies of Calcium Channels
Pathologies of Calcium Channels
Norbert Weiss and Alexandra Koschak
The two enantiomers of Remacemide and those of APL 12495AA have been tested for their anticonvulsive properties and the potency of the drugs were different depending on the route of administration and type of seizure test ( Garske et al.
Advances in Research on Neurodegeneration: Volume 6
Advances in Research on Neurodegeneration: Volume 6
W. Poewe, G. Ransmayr, 1999
An initial tolerability trial has been conducted with Remacemide in HD patients ( Kieburtz et al., 1996). In this randomized, parallel group, double-blind, placebo- controlled dosage-ranging trial 31 patients were randomized to 3 arms (placebo,  ...
Excitatory Amino Acids: Clinical Results with Antagonists
Excitatory Amino Acids: Clinical Results with Antagonists
1997
Glutamate is the major excitatory neurotransmitter in the brain and dysfunction of glutamate transmission is the likely cause of a variety of diseases including neurodegeneration following cerebral ischemia, Huntington's chorea, amyotrophic lateral sclerosis, epilepsy, spasticity, emesis, chronic pain, and schizophrenia. Excitatory amino acid ...
Perioperative Medicine: Managing for Outcome
Perioperative Medicine: Managing for Outcome
Mark F. Newman, Lee A. Fleisher, Mitchell P. Fink, 2008
Remacemide Because excitotoxicity plays a central role in cerebral ischemic injury, it was an obvious target in the ... patients scheduled for CABG were given Remacemide orally for 4 days preoperatively.174 A neurocog- nitive battery was ...
Primate Models of Children's Health and Developmental ...
Primate Models of Children's Health and Developmental ...
Thomas Burbacher, Kimberly Grant, Gene P. Sackett, 2011
There was also a significant effect of Remacemide to delay the acquisition of color and position discrimination task performance. However, by the end of treatment CPR performance by these animals was no different from any other group ...
Development of Google searches


Blog posts on the term
Remacemide
Heal Parkinson's: Remacemide Hydrochloride
Remacemide Hydrochloride as Monotherapy for Parkinson’s Disease Pasted from.
healparkinsons.blogspot.com/2012/04/remacemide-hydrochloride.html
Side Effects Of Co Q10: Read This Before You Take It.
Research has shown that Co Q10 is great for heart health. But what about the side effects of Co Q10? Always know what you are taking.
www.optimal-heart-health.com/side_effects_of_co_q10.html
Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
Parkinson’s Disease is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of Parkinson’s disease.
www.hindawi.com/journals/pd/2013/196028/
JAMA Network | JAMA Neurology | Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease: The TREND-HD Study
archneur.jamanetwork.com/article.aspx?articleid=1107464
Sign In
intl-aop.sagepub.com/content/44/12/1896.full
Matteo Marti | Profiling - I profili dell'abuso
www.onap-profiling.org/matteo-marti-2/
Developing Rapid Onset Antidepressant Drugs That Act at the NMDA Receptor : Bipolar Network News
bipolarnews.org/?p=1369
Orphanet Journal of Rare Diseases | Full text | Huntington's disease: a clinical review
Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia. Prevalence in the Caucasian population is estimated at 1/10,000-1/20,000. Mean age at onset of symptoms is 30-50 years. In some cases symptoms start before the age of 20 years with behavior disturbances and learning difficulties at school (Juvenile Huntington's disease; JHD). The classic sign is chorea that gradually spreads to all muscles. All psychomotor processes become severely retarded. Patients experience psychiatric symptoms and cognitive decline. HD is an autosomal dominant inherited disease caused by an elongated CAG repeat (36 repeats or more) on the short arm of chromosome 4p16.3 in the Huntingtine gene. The longer the CAG repeat, the earlier the onset of disease. In cases of JHD the repeat often exceeds 55. Diagnosis is based on clinical symptoms and signs in an individual with a parent with proven HD, and is confirmed by DNA determination. Pre-manifest diagnosis should only be performed by multidisciplinary teams in healthy at-risk adult individuals who want to know whether they carry the mutation or not. Differential diagnoses include other causes of chorea including general internal disorders or iatrogenic disorders. Phenocopies (clinically diagnosed cases of HD without the genetic mutation) are observed. Prenatal diagnosis is possible by chorionic villus sampling or amniocentesis. Preimplantation diagnosis with in vitro fertilization is offered in several countries. There is no cure. Management should be multidisciplinary and is based on treating symptoms with a view to improving quality of life. Chorea is treated with dopamine receptor blocking or depleting agents. Medication and non-medical care for depression and aggressive behavior may be required. The progression of the disease leads to a complete dependency in daily life, which results in patients requiring full-time care, and finally death. The most common cause of death is pneumonia, followed by suicide.
www.ojrd.com/content/5/1/40
qna - Start To Diminish
www.vfxlab.co.kr/xe/index.php?document_srl=169083
Feeding Frenzy—Therapeutics Tap Tryptophan, Cathepsins, HDACs, Zinc | ALZFORUM
www.alzforum.org/new/detail.asp?id=2808
123